Policy News

      • 10 October, 2019

    ISSCR Comments on Brazil’s Advanced Therapy Medicinal Products Regulation

    The ISSCR submitted comments to Brazil’s health regulatory agency (ANVISA) regarding the proposed regulations for advanced therapy medicinal products that urge national governments to “maintain rigorous review pathways to ensure that stem cell-based products conform to the highest standards of evidence-based medicine.”
    Full story
      • 8 October, 2019

    Lawrence Goldstein Policy Fellows Announced

    The ISSCR is pleased to announce the recipients of the inaugural Lawrence Goldstein Policy Fellowship, Mohamed Abou El-Enein, PhD (Charité Universitätsmedizin, Berlin, Germany) and Zubin Master, PhD (Mayo Clinic, Rochester, MN, U.S.).
    Full story
      • 7 October, 2019

    ISSCR Policy Advocacy in Action

    Polices created by legislators and regulators can have a profound impact on stem cell and biomedical research and the development of new treatments. The ISSCR has been working on several fronts to advocate for responsible stem cell research and its application. Read more about the recent ISSCR-led fly in to Washington D.C. for discussions with government officials and our consultations with Google to prevent the marketing of unproven stem cell therapies.
    Full story
      • 6 September, 2019

    ISSCR Applauds Google’s New Policy Banning Ads on Unproven Therapies

    The International Society for Stem Cell Research (ISSCR) today released the following statement regarding Google’s new policy that bans advertisements from unproven stem cell clinics and other speculative medical interventions.
    Full story
      • 12 August, 2019

    The ISSCR Releases Informed Consent Standard for Stem Cell-based Interventions

    The International Society for Stem Cell Research (ISSCR) today released a professional standard of informed consent for stem cell-based interventions performed outside of formal clinical trials, such as the unapproved and unproven “treatments” offered by clinicians at direct-to-consumer clinics. The standard is meant to help ensure that patients are informed about the potential benefits and risks of stem cell-based medical interventions, and was developed with input from clinicians, ethicists, researchers, and regulators from around the world.
    Full story
      • 26 June, 2019

    The ISSCR Announces Establishment of Lawrence Goldstein Science Policy Fellowship

    The ISSCR honored longtime member Lawrence Goldstein for his years of science policy advocacy, and announced a new program in his name that will train ISSCR members to become stem cell policy advocates. The tribute and introduction of the Lawrence Goldstein Science Policy Fellowship program was part of the opening plenary session of the ISSCR annual meeting, 26-29 in Los Angeles, Calif., U.S.
    Full story
      • 13 June, 2019

    ISSCR Supports Amendment in U.S. Congress to Prevent Fetal Tissue Research Funding Restrictions

    The ISSCR and other medical, scientific, educational, and healthcare groups sent a letter to members of the U.S. Congress supporting an amendment that would prevent the implementation of a new policy to restrict and delay federal funding for fetal tissue research.
    Full story
      • 7 June, 2019

    ISSCR Applauds Landmark Court Ruling in Favor of FDA Regulating Stem Cell Therapies Offered by Florida Clinic

    The ISSCR commends the U.S. District Court ruling that confirms the FDA’s authority to regulate clinics marketing and selling unproven therapies as stem cell products. The clinic, U.S. Stem Cell, has injected cells derived from fat into the eyes of several patients, resulting in at least three being blinded.
    Full story
      • 5 June, 2019

    ISSCR Opposes Health and Human Services Policy Restricting Fetal Tissue Research

    The International Society for Stem Cell Research (ISSCR), the largest professional organization of stem cell researchers from around the world, opposes the new U.S. Health and Human Services policy to eliminate federal funding for fetal tissue research in the National Institutes of Health (NIH) intramural research program. This research has long been viewed as good public policy to improve human health and has proceeded with public support.
    Full story
      • 24 May, 2019

    ISSCR Comments on China's Proposed Regulations for Cell Therapies

    The ISSCR has submitted comments to China's National Medical Products Administration regarding China's draft regulations for the Management of Clinical Research and Transformation Applications for Somatic Cell Therapy.
    Full story